跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 128 条关于
“NXP100”
全部
128
临床试验
86
药物
30
机构
0
资讯
12
2个月前
Nuvectis In-Licenses Two Clinical-Stage Assets from Haisco, Transforming into Late-Stage Biopharma with Oral Factor B and Paradox-Breaker BRAF Inhibitors
去年
Nuvectis Pharma Reports Financial Results and Highlights Clinical Progress of NXP800 and NXP900
2年前
NXP800 Receives FDA Orphan Drug Designation for ARID1a-Deficient Ovarian Cancers
去年
Nuvectis Pharma to Present Promising NXP900 Data at 2025 AACR Meeting
去年
Nuvectis Pharma's NXP800 Shows Promise in ARID1a-Mutated Ovarian Cancer Trial
去年
NXP800 Shows Promise in Overcoming Hormone Resistance in Advanced Prostate Cancer
9个月前
Nuvectis Pharma Initiates Phase 1b Combination Study of NXP900 with Osimertinib for Resistant EGFR-Mutated NSCLC
6个月前
Nuformix Secures FDA Orphan Drug Designation for Inhaled IPF Therapy NXP002
去年
Kinoxis Therapeutics Receives $2.5M Grant to Advance KNX100 for Dementia Agitation
去年
FDA Grants Rare Pediatric Disease Designation to NEO100 for Aggressive Childhood Brain Cancer
第 1 页,共 2 页
上一页
下一页